Intrahepatic Cholangiocarcinoma (ICC)
Conditions
Brief summary
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Interventions
DRUGICP-192
ICP-192 is a round, uncoated tablet, 5mg, orally.
Sponsors
Beijing InnoCare Pharma Tech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed the ICF and Age ≥ 18 years old, either sex. 2. ECOG score of 0-1. 3. Life expectancy \> 3 months. 4. Histopathologically or cytopathologically confirmed intrahepatic cholangiocarcinoma with unresectable, recurrent or metastatic (AJCC 2017, 8th edition, TNM stage IV) tumor that has progressed following at least one line of chemotherapy and progression/recurrence within 6 months after neoadjuvant/adjuvant chemotherapy may be included. 5. FGFR2 fusion /rearrangement as confirmed by the central laboratory. 6. At least one measurable lesion at screening as target lesion per RECIST 1.1. 7. Organ functions meeting the protocol requirements. 8. Contraception according to the protocol requirements.
Exclusion criteria
1. Presence of other malignancies requiring medical intervention. 2. Prior treatment with selective FGFR inhibitors or FGFR antibodies. 3. Treatment with biological products, radical radiotherapy, and other investigational drugs within 4 weeks prior to the first dose of study drug. Chemotherapy within 3 weeks prior to the first dose of study drug. 4. Known symptomatic central nervous system (CNS) metastases. 5. Patients who have not recovered from the toxicity caused by previous anti-tumor treatment and have ≥ Grade 2 adverse events (judged per CTCAE V5.0 evaluation criterion) at the first dose of study drug. 6. Currently uncontrolled cardiovascular and cerebrovascular diseases, or a past medical history. 7. Any unstable or uncontrolled systemic disease as judged by the investigator, such as: active infection requiring intravenous therapy, uncontrolled hypertension (After treatment systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 90 mmHg), and diabetes mellitus (HbA1c \> 8%). 8. Current active bleeding, such as deep venous thrombosis, portal hypertension signs leading to gastroesophageal venous bleeding. 9. Wound with active infection. 10. Major surgical procedures within 4 weeks prior to the first dose of the study drug or minor surgical procedures within 2 weeks prior to the first dose of the study drug. 11. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity 12. History and/or current evidence of extensive tissue calcification, including but not limited to calcification in soft tissues, kidney, intestine, myocardium, vasculature and/or the lungs, with the exception of lymph node calcification, mild pulmonary parenchymal calcification, and asymptomatic coronary artery calcification. 13. Clinically serious gastrointestinal dysfunction that may affect the intake, transport or absorption of the study drug (such as poorly controlled nausea, vomiting, diarrhea; malabsorption syndrome; intestinal obstruction and small bowel resection, etc.), or the patient was unable to swallow the drug orally. 14. Active HBV infection, Active HCV infection, HIV infection. 15. Female subjects who are pregnant or breastfeeding, or plan to have a pregnancy within 6 months after the last dose of the study drug; or male subjects who plan to father a child during the study or within 6 months after the last dose of the study drug. 16. The last dose of strong CYP3A inhibitor or CYP3A inducer (including food, western medicine, traditional Chinese medicine) is less than 5 half-lives before the first dose of study drug, or plans to take concomitant drugs or foods with strong CYP3A inhibition or induction during the study. 17. Known allergy to any excipients of the study drug. 18. Subjects with conditions that in the investigator's opinion are not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | Up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | Up to 3 years |
| Disease control rate (DCR) | Up to 3 years |
| Duration of response (DOR) | Up to 3 years |
| Time to response (TTR) | Up to 3 years |
| Overall survival (OS) | Up to 3 years |
| The adverse event (AE) of ICP-192 assessed by NCI-CTCAE V5.0 | Up to 3 years |
| Time to maximum concentration (Tmax) | Up to 3 years |
| Half-life (T1/2) | Up to 3 years |
| Area under the concentration-time curve (AUC) | Up to 3 years |
| Apparent clearance (CL/F) | Up to 3 years |
| Terminal apparent volume of distribution (Vz/F) | Up to 3 years |
| Maximum concentration (Cmax) | Up to 3 years |
Other
| Measure | Time frame |
|---|---|
| To explore the relationship between blood phosphorus and clinical efficacy | Up to 3 years |
Countries
China
Contacts
Primary ContactJin Li
Outcome results
None listed